new york times semaglutide The Presents: 'Weight of the World' on Ozempic's Rise A Game Changer': Drug Brings

This omission is particularly alarming given the proven efficacy of GLP-1RAs in glycemic control and weight reduction, which are essential components of comprehensive diabetes care

Even light walking after dinner can help get your digestive system moving, says Dr

After lunch, nutrition whiz Christine Craig, MS, RDN, CDCES expertly details the latest in MNT and provides real strategies on translating this content to your clinical practice

Farxiga/Forxiga is not currently approved for weight loss as a standalone indication in non-diabetics, but the evidence is accumulating: Currently, if weight loss is the primary goal in a non-diabetic patient, GLP-1 agonists (semaglutide/Ozempic, tirzepatide/Mounjaro) produce substantially greater weight loss (1015% vs 24%)

Most patients experience mild nausea and reduced appetite

doi: 10.1038/s42255-019-0041-z 74 SharmaAMahMRitchieRHDe BlasioMJ